𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Μultiple myeloma developing after imatinib mesylate therapy for chronic myeloid leukemia

✍ Scribed by A. Galanopoulos; S. I. Papadhimitriou; E. Kritikou-Griva; M. Georgiakaki; N. I. Anagnostopoulos

Publisher
Springer
Year
2008
Tongue
English
Weight
56 KB
Volume
88
Category
Article
ISSN
0939-5555

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Acute myeloid leukemia developing during
Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities
✍ Attaphol Pawarode; Sheila N.J. Sait; Alain Nganga; Lionel J. Coignet; Maurice Ba 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 171 KB

The BCR/ABL tyrosine kinase inhibitor imatinib mesylate produces a high rate of cytogenetic responses in patients with Philadelphia (Ph)-positive chronic myeloid leukemia (CML), but secondary clonal chromosome abnormalities may develop in Ph-negative cells, and acute myeloid leukemia (AML) has been

Philadelphia-negative acute myeloid leuk
Philadelphia-negative acute myeloid leukemia with new chromosomal abnormalities developing after first-line imatinib treatment for chronic phase chronic myeloid leukemia
✍ Carmen Fava; Jorge Cortes 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 306 KB 👁 2 views

## Induction of integrin b 1 expression in bone marrow cells after chemotherapy correlates with the overexpression of lung resistance protein and poor outcome in patients with multiple myeloma To the Editor: Acquired drug resistance continues to be one of the major obstacles hindering the successf

Imatinib mesylate therapy in chronic mye
Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rate
✍ Giuliana Alimena; Massimo Breccia; Luigia Luciano; Fabrizio Quarantelli; Daniela 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 205 KB

To determine the impact on minimal residual disease by switching to imatinib chronic phase chronic myeloid leukaemia (CP-CML) patients responsive to interferon-alpha (IFNalpha), in stable complete cytogenetic response (CCR) but with persistent PCR positivity. Twenty-six Philadelphia positive (Ph+) C